Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

This was the stock's second consecutive day of losses.

Humana (HUM) backs reforms on extra Medicare Advantage payments from home visits and chart review. Read more here.

Humana Inc. closed 43.21% below its 52-week high of $406.46, which the company reached on July 18th.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $307.44, ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Enphase Energy (ENPH) was the worst-performing stock in the S&P 500 ... in well below estimates on falling gas prices. Shares of Humana (HUM) and other health insurance providers declined as ...

Shares of Humana and other health insurance providers ... Enphase Energy (ENPH) was the worst-performing stock in the S&P 500, and shares of rivals in the solar sector were also down, as the ...

Given Humana's weak financial performance since 2023 due to a mismatch in rates and utilization in MA and the potential for low MA bonus payments in 2026 due to weak star ratings, a major cash ...